Welcome to the website of Michael Schlander,

Professor of Health Economics at the University of Heidelberg
and
Head of Division of Health Economics at German Cancer Research Center (DKFZ)
Founder and Chairman of InnoVal^HC,
Institute for Innovation & Valuation in Health Care
[member, Stockholm Network of European Think Tanks]

News

2021

15-10-2021 21:42

Study on "HTA in England, France and Germany"

Comparative study on "Health technology assessment (HTA) in England, France and Germany: What do matched drug pairs tell us about recommendations by national HTA agencies?" in the Journal of Comparative Effectiveness Research (online available as of September 2021).

11-10-2021 16:10

Article on "Resource allocation in the Covid-19 health crisis"

Recently published paper on "Resource allocation in the Covid-19 health crisis: are Covid-19 preventive measures consistent with the Rule of Rescue?" in the scientific journal Medicine, Health Care and Philosophy (online available as of August 2021).

30-09-2021 07:46

How Much Does it Cost to Research and Develop a New Drug?

Recently published: "How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment" in the well-known journal PharmacoEconomics - evaluating the range and suitability of published R&D cost estimates as to the degree to which they represent the actual costs of industry (online available as of August 2021).

09-09-2021 17:46

Study on "Income loss after a cancer diagnosis in Germany"

Recently published study on "Income loss after a cancer diagnosis in Germany: An analysis based on the socio-economic panel survey" in the scientific journal Cancer Medicine, which is the first attempt to measure - on the German national level - the magnitude of absolute income loss after a cancer diagnosis.